ATE378342T1 - Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate - Google Patents

Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate

Info

Publication number
ATE378342T1
ATE378342T1 AT02721033T AT02721033T ATE378342T1 AT E378342 T1 ATE378342 T1 AT E378342T1 AT 02721033 T AT02721033 T AT 02721033T AT 02721033 T AT02721033 T AT 02721033T AT E378342 T1 ATE378342 T1 AT E378342T1
Authority
AT
Austria
Prior art keywords
polymeric
containing same
linkers
conjugates containing
terminally branched
Prior art date
Application number
AT02721033T
Other languages
English (en)
Inventor
Yun Choe
Richard Greenwald
Original Assignee
Enzon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzon Inc filed Critical Enzon Inc
Application granted granted Critical
Publication of ATE378342T1 publication Critical patent/ATE378342T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyethers (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Graft Or Block Polymers (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT02721033T 2001-02-20 2002-02-19 Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate ATE378342T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27000901P 2001-02-20 2001-02-20

Publications (1)

Publication Number Publication Date
ATE378342T1 true ATE378342T1 (de) 2007-11-15

Family

ID=23029515

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02721033T ATE378342T1 (de) 2001-02-20 2002-02-19 Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate

Country Status (10)

Country Link
US (1) US20020183259A1 (de)
EP (1) EP1362053B1 (de)
JP (1) JP2004532289A (de)
AT (1) ATE378342T1 (de)
AU (1) AU2002251988A1 (de)
CA (1) CA2437989A1 (de)
DE (1) DE60223499T2 (de)
DK (1) DK1362053T3 (de)
MX (1) MXPA03007392A (de)
WO (1) WO2002065988A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6624142B2 (en) * 1997-12-30 2003-09-23 Enzon, Inc. Trimethyl lock based tetrapartate prodrugs
US7056500B2 (en) 2001-10-18 2006-06-06 Nektar Therapeutics Al, Corporation Polymer conjugates of opioid antagonists
US7332164B2 (en) * 2003-03-21 2008-02-19 Enzon Pharmaceuticals, Inc. Heterobifunctional polymeric bioconjugates
AU2004230927B9 (en) 2003-04-13 2011-12-01 Enzon Pharmaceuticals, Inc. Polymeric oligonucleotide prodrugs
KR101163683B1 (ko) 2003-05-12 2012-07-10 아피맥스, 인크. 에리스로포이에틴 수용체에 결합하는 신규의 펩티드
PL1625156T3 (pl) 2003-05-12 2013-03-29 Affymax Inc Peptydy wiążące się do receptora erytropoetyny
JP2007530440A (ja) * 2003-05-12 2007-11-01 アフィーマックス・インコーポレイテッド 新規ポリ(エチレングリコール)修飾化合物およびその用途
CN1849141A (zh) * 2003-05-12 2006-10-18 阿费麦克斯公司 用于聚(乙二醇)修饰的肽的间隔臂部分
US20060182692A1 (en) 2003-12-16 2006-08-17 Fishburn C S Chemically modified small molecules
CN1925875A (zh) 2003-12-16 2007-03-07 尼克塔治疗亚拉巴马公司 化学改性的小分子
CN101023119B (zh) * 2004-09-22 2010-05-05 日本化药株式会社 新型嵌段共聚物,胶束制剂以及含胶束制剂为活性组分的抗癌剂
CA2606939C (en) * 2005-05-11 2013-09-03 Nippon Kayaku Kabushiki Kaisha Polymeric derivative of cytidine metabolic antagonist
US7550433B2 (en) 2005-06-03 2009-06-23 Affymax, Inc. Erythropoietin receptor peptide formulations and uses
CA2611823C (en) 2005-06-16 2013-07-30 Nektar Therapeutics Al, Corporation Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates
KR20080106254A (ko) 2006-03-28 2008-12-04 니폰 가야꾸 가부시끼가이샤 탁산류의 고분자 결합체
CA2652656A1 (en) 2006-05-18 2007-11-29 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of podophyllotoxins
CA2658100A1 (en) * 2006-07-19 2008-01-24 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of combretastatins
MX2009002855A (es) * 2006-09-15 2009-03-30 Enzon Pharmaceuticals Inc Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales.
CA2664852A1 (en) * 2006-10-03 2008-04-10 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of resorcinol derivatives
EP2080779B1 (de) 2006-11-06 2016-05-18 Nippon Kayaku Kabushiki Kaisha Polymeres derivat eines nucleinsäuremetabolismus-antagonisten
EP2090607B1 (de) * 2006-11-08 2015-05-20 Nippon Kayaku Kabushiki Kaisha Polymerderivat eines nukleinsäuremetabolismus-antagonisten
US8106154B2 (en) 2007-01-31 2012-01-31 Affymax, Inc. Nitrogen-based linkers for attaching modifying groups to polypeptides and other macromolecules
US8703878B2 (en) 2007-09-28 2014-04-22 Nippon Kayaku Kabushiki Kaisha High-molecular weight conjugate of steroids
KR101589582B1 (ko) * 2008-03-18 2016-01-28 니폰 가야꾸 가부시끼가이샤 생리활성물질의 고분자량 결합체
JP5366940B2 (ja) 2008-05-08 2013-12-11 日本化薬株式会社 葉酸若しくは葉酸誘導体の高分子結合体
JP5544357B2 (ja) 2009-05-15 2014-07-09 日本化薬株式会社 水酸基を有する生理活性物質の高分子結合体
SI2621496T2 (sl) 2010-09-30 2019-04-30 Astrazeneca Ab Kristalinični konjugat naloksol-PEG
JP5856069B2 (ja) 2010-11-17 2016-02-09 日本化薬株式会社 新規なシチジン系代謝拮抗剤の高分子誘導体
HK1198628A1 (en) * 2011-08-12 2015-05-22 Ascendis Pharma A/S Polymeric hyperbranched carrier-linked prodrugs
JP5711378B2 (ja) 2011-09-11 2015-04-30 日本化薬株式会社 ブロック共重合体の製造方法
AU2019296174B2 (en) 2018-06-29 2021-10-07 Changchun Changcheng Pharmaceutical Technology Co., LTD Phosphorus-containing prodrugs of gemcitabine

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
IL83966A (en) * 1986-09-26 1992-03-29 Schering Ag Amides of aminopolycarboxylic acids and pharmaceutical compositions containing them
US4943579A (en) * 1987-10-06 1990-07-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Water soluble prodrugs of camptothecin
JP2958019B2 (ja) * 1988-05-06 1999-10-06 住友製薬株式会社 ポリエチレングリコール誘導体、修飾ペプチドおよびその製造方法
US5112739A (en) * 1988-08-02 1992-05-12 Polaroid Corporation Enzyme controlled release system
US5283339A (en) * 1988-11-23 1994-02-01 California Institute Of Technology Immobilized metal aqueous two-phase extraction and precipitation
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US6039931A (en) * 1989-06-30 2000-03-21 Schering Aktiengesellschaft Derivatized DTPA complexes, pharmaceutical agents containing these compounds, their use, and processes for their production
EP0510080A4 (en) * 1989-12-26 1992-12-02 Nova Pharmaceutical Corporation Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use
US5552391A (en) * 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5130126A (en) * 1990-07-09 1992-07-14 Nippon Oil & Fats Co., Ltd. Polymer-drug conjugate and a method of producing it
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
US5433886A (en) * 1992-05-07 1995-07-18 Calgon Corporation Stabilization of polyether polyamino methylene phosphonate scale inhibitors against degradation by bromine and chlorine biocides
AU4406793A (en) * 1992-06-04 1993-12-30 Clover Consolidated, Limited Water-soluble polymeric carriers for drug delivery
GB9213077D0 (en) * 1992-06-19 1992-08-05 Erba Carlo Spa Polymerbound taxol derivatives
US5614549A (en) * 1992-08-21 1997-03-25 Enzon, Inc. High molecular weight polymer-based prodrugs
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5756825A (en) * 1992-09-08 1998-05-26 Safavy; Ahmad Hydroxamic acid-based bifunctional chelating compounds
KR950703582A (ko) * 1992-10-14 1995-09-20 조이스 이. 마임스 킬레이트화 중합체(chelating polymers)
US5349001A (en) * 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) * 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5547981A (en) * 1993-03-09 1996-08-20 Enzon, Inc. Taxol-7-carbazates
US5454954A (en) * 1993-09-21 1995-10-03 Calgon Corporation Scale control in metal mining circuits using polyether polyamino methylene phosphonates
WO1995011020A1 (en) * 1993-10-20 1995-04-27 Enzon, Inc. 2'- and/or 7- substituted taxoids
US5880131A (en) * 1993-10-20 1999-03-09 Enzon, Inc. High molecular weight polymer-based prodrugs
US5965566A (en) * 1993-10-20 1999-10-12 Enzon, Inc. High molecular weight polymer-based prodrugs
US5840900A (en) * 1993-10-20 1998-11-24 Enzon, Inc. High molecular weight polymer-based prodrugs
US5919455A (en) * 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) * 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605976A (en) * 1995-05-15 1997-02-25 Enzon, Inc. Method of preparing polyalkylene oxide carboxylic acids
US5646159A (en) * 1994-07-20 1997-07-08 Research Triangle Institute Water-soluble esters of camptothecin compounds
US5672335A (en) * 1994-11-30 1997-09-30 Schering Aktiengesellschaft Use of metal complexes as liver and gallbladder X-ray diagnostic agents
US5489589A (en) * 1994-12-07 1996-02-06 Bristol-Myers Squibb Company Amino acid derivatives of paclitaxel
GB9501052D0 (en) * 1995-01-19 1995-03-08 Cancer Res Campaign Tech Improvements relating to prodrugs
US5672584A (en) * 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US5679852A (en) * 1995-06-02 1997-10-21 Schering Aktiengesellschaft Process for the production of DTPA-monoamides of the central carboxylic acid and their use as pharmaceutical agents
DE69533615T2 (de) * 1995-06-27 2005-10-13 Pharmachemie B.V. Anthracyclin Prodrugs, Verfahren zu deren Herstellung und deren Verwendung in der selektiven Chemotherapie
US6020373A (en) * 1995-10-20 2000-02-01 Eastern Virginia Medical School Chelate derivatives as protectors against tissue injury
TW520293B (en) * 1995-11-22 2003-02-11 Univ Johns Hopkins Med Delivery system to enhance cellular uptake of biomolecules
US6011042A (en) * 1997-10-10 2000-01-04 Enzon, Inc. Acyl polymeric derivatives of aromatic hydroxyl-containing compounds
US6135655A (en) * 1997-10-14 2000-10-24 Hewlett-Packard Company Multipixel dots in monochrome drop-on-demand printing
US5965119A (en) * 1997-12-30 1999-10-12 Enzon, Inc. Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same

Also Published As

Publication number Publication date
AU2002251988A1 (en) 2002-09-04
MXPA03007392A (es) 2003-12-04
WO2002065988A2 (en) 2002-08-29
DE60223499T2 (de) 2008-10-16
DK1362053T3 (da) 2008-03-10
CA2437989A1 (en) 2002-08-29
EP1362053A4 (de) 2005-01-19
US20020183259A1 (en) 2002-12-05
DE60223499D1 (de) 2007-12-27
EP1362053B1 (de) 2007-11-14
EP1362053A2 (de) 2003-11-19
WO2002065988A3 (en) 2003-04-10
JP2004532289A (ja) 2004-10-21

Similar Documents

Publication Publication Date Title
DE60223499D1 (de) Terminal verzweigte, polymere linker und diese enthaltende polymere konjugate
ATE378071T1 (de) Endgruppenverzweigte polymere verbindungen und diese enthaltende polymere konjugate
CY1121983T1 (el) Παραγωγο ραπαμυκινης για τη θεραπευτικη αντιμετωπιση καρκινου του παγκρεατος
NO20013451L (no) 1-Heterocyklus-substituerte diarylaminer
MXPA01007777A (es) Bio-materiales formadas por reaccion de adicion nucleofila a grupos insaturados conjugados.
AU7522601A (en) Conjugate addition reactions for the controlled delivery of pharmaceutically active compounds
DK1093819T3 (da) Forbindelse og præparat til tilförsel af aktive midler
TR200103574T2 (tr) Amid ikameli/katkılı imidazokinolinler
EP3449946A3 (de) Hydrophobe kernträgerzusammensetzungen zur verabreichung von therapeutika, verfahren zur herstellung und verwendung davon
DE60239707D1 (de) Antimikrobielle kationische peptide und diese enthaltende formulierungen
DK1200412T3 (da) Antiproliferative imidazolforbindelser
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
MXPA02012817A (es) Drogas antineoplasicas liposomales y uso de las mismas.
CY1105538T1 (el) Ιατρικη μορφοποιηση αερολυματος
MY136520A (en) Novel compounds
PL356904A1 (en) Pharmaceutical compositions
IL166561A0 (en) Pharmaceutical compositions
TR199901104T2 (xx) Farmas�tik bile�ikler.
IL157540A0 (en) N-(aryl)-2-arylethenesulphonamides and therapeutic uses thereof
HUP0100350A2 (hu) A prosztatarák kezelésére alkalmazható konjugátumok, azokat hatóanyagként tartalmazó gyógyászati készítmények, elárás ezek előállítására, valamint alkalmazásuk
HRP20080569T3 (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
HK1040486A1 (zh) 脂肪酸-抗癌共軛和其用途
DK1666924T3 (da) Kovalent bundne, hydrofile belægningssammensætninger til implantater
NO20014803D0 (no) Pyrido-tieno-diazepiner, fremgangsmåte for fremstilling derav og farmasöytiske blandinger inneholdende dem
TR200001014A3 (tr) Gelistirilmis polimer kompozisyonlari hazirlanmasi için islem.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties